Codexis, Inc. (CDXS)

NASDAQ: CDXS · IEX Real-Time Price · USD
3.490
-0.020 (-0.57%)
At close: Mar 28, 2024, 4:00 PM
3.495
+0.005 (0.14%)
After-hours: Mar 28, 2024, 7:16 PM EDT

Company Description

Codexis, Inc. discovers, develops, and sells enzymes and other proteins.

The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.

The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.

The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency.

The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe.

The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis, Inc.
Codexis logo
Country United States
Founded 2002
IPO Date Apr 22, 2010
Industry Biotechnology
Sector Healthcare
Employees 174
CEO Dr. Stephen George Dilly MBBS, Ph.D.

Contact Details

Address:
200 Penobscot Drive
Redwood City, California 94063
United States
Phone 650-421-8100
Website codexis.com

Stock Details

Ticker Symbol CDXS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001200375
CUSIP Number 192005106
ISIN Number US1920051067
Employer ID 71-0872999
SIC Code 2860

Key Executives

Name Position
Dr. Stephen George Dilly MBBS, Ph.D. President, Chief Executive Officer and Director
Kevin Norrett M.B.A., M.S. Chief Operating Officer
Margaret Fitzgerald J.D. Chief Legal and Compliance Officer, General Counsel and Secretary
Sriram Ryali M.B.A. Chief Financial Officer
Carrie McKim Director of Investor Relations
Karen Frechou-Armijo Senior Vice President and Head of Human Resources
Dr. Stefan Lutz Ph.D. Senior Vice President of Research
Robert Sato M.B.A., Ph.D. Senior Vice President of Pharmaceutical Development, Quality and Regulatory

Latest SEC Filings

Date Type Title
Mar 6, 2024 8-K Current Report
Feb 28, 2024 10-K Annual Report
Feb 28, 2024 8-K Current Report
Feb 16, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 8-K Current Report
Feb 9, 2024 8-K Current Report
Feb 9, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 24, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals